Low-Dose Methotrexate Tolerance Regimen for Alloimmunization Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current clinical interventions are inadequate for preventing alloimmunization and alloimmune sequelae in allogeneic transfusions and transplantations, particularly due to the challenges of finding perfect donor-recipient matches and the side effects of existing immunosuppressive agents, leading to complications like platelet refractoriness and transplant rejection.

Innovation Solution

A transient low-dose methotrexate (TLD-MTX) regimen is administered concurrently with allogeneic transfusions, followed by additional doses to induce long-term immune tolerance, reducing alloimmunization and alloimmune sequelae by enhancing regulatory B cells and T cells, and skewing the alloantibody response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current immunosuppressive agents (cyclosporine A, CTLA-Ig) are used to prevent alloimmunization, then alloimmunization risk is reduced, but significant immunosuppressive side effects occur

Engineering Contradiction:

Improveprevention of alloimmunizationVSAvoidimmunosuppressive side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the dosage parameters of methotrexate from conventional high doses to low doses (0.1-10 mg/m²), and modifies the administration timing to be transient (only during initial transfusions rather than continuous). This parameter transformation allows the drug to induce immune tolerance without causing severe immunosuppression, thereby resolving the contradiction between prevention efficacy and side effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

Instead of continuous immunosuppression, the patent employs periodic transient administration of methotrexate only during the initial phase of transfusion (first 1-5 transfusions). This time-based strategy allows immune tolerance to be established during the critical early period while avoiding prolonged immunosuppressive side effects, thus resolving the contradiction between immediate protection and long-term safety

Inventive Principle:

Principle #19Periodic action

2Reliability

If donor-recipient matching is performed to prevent alloimmunization, then immune response is reduced, but finding perfect matches becomes increasingly difficult and costly

Engineering Contradiction:

Improveprevention of alloimmunizationVSAvoidcomplexity of matching process

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts the white blood cells (which contain the problematic MHC antigens) from the platelet transfusion product through enhanced leukoreduction, while retaining the therapeutic platelets. By removing the immunogenic component while preserving the beneficial component, the invention eliminates the need for complex donor-recipient MHC matching, thus resolving the contradiction between prevention efficacy and system complexity

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces transient low-dose methotrexate as an intermediary agent that mediates between the donor platelets and recipient immune system. The drug temporarily modulates the recipient's immune response during the critical initial exposure period, allowing acceptance of allogeneic platelets without requiring precise donor-recipient matching, thereby simplifying the transfusion system

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If multiple allogeneic transfusions are administered to treat blood disorders, then patient condition is improved, but risk of alloimmunization increases due to repeated exposure to platelet antigens

Engineering Contradiction:

Improvetreatment efficacyVSAvoidrisk of alloimmunization

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies preliminary action by administering methotrexate during the initial transfusions before alloimmunization can develop. This preemptive approach establishes immune tolerance during the first 1-5 transfusions, creating protective immunity that persists through subsequent therapeutic transfusions, thus allowing continued treatment without increased alloimmunization risk

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent converts the harmful repeated exposure to platelet antigens into a beneficial opportunity for inducing immune tolerance. By deliberately exposing the patient to controlled amounts of allogeneic platelets during the initial phase with concurrent methotrexate administration, the treatment transforms what would normally be immunogenic exposure into a tolerance-inducing event that protects against future alloimmunization

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20260060988A1Transient low-dose methotrexate for tolerance to alloimmunity

Publication Date: 2026.03.05 VITALANT

AI summary

Methods and compositions for inducing immunotolerance in a subject to allogeneic transfusions and transplantations are provided. Further provided are methods for preventing or reducing alloimmunization and/or alloimmune sequelae.